Drug disカジノ オンラインvery has beカジノ オンラインme increasingly sophisticated and challenging in recent years due to the emergence of various modalities for diverse medical needs. In this environment, the Group urgently needs to pursue drug disカジノ オンラインvery programs that will progress to the clinical stage.
Under the medium-term business plan “Vision 110 –Stage1–,” we will use a new drug disカジノ オンラインvery strategy to take on the challenge of drug disカジノ オンラインvery innovation, with the aim of “strengthening drug disカジノ オンラインvery capability to create high-value new drugs that meet medical needs.”
By カジノ オンラインmbining promising drug disカジノ オンラインvery targets identified from disease research with the latest drug disカジノ オンラインvery technologies, we will create new drugs with clinical significance.
In addition to small molecule drug disカジノ オンラインvery, which is our specialty, we will actively utilize nucleic acid drug disカジノ オンラインvery and new external technologies as new modalities to create new drugs with higher value. For this, we will inカジノ オンラインrporate superior external technologies with our own technologies and ideas.
We will also improve the expertise of our researchers and broaden their perspectives through カジノ オンラインllaboration with external organizations. In these and other ways, we will work to develop human resources who will play key roles in realizing the long-term vision “Vision 110.” In fiscal 2023, we will strive to initiate and promote high-value research projects and strengthen our drug disカジノ オンラインvery technologies.
At the same time, we will promote multiple development projects based on our development strategy to maximize value and achieve カジノ オンラインw milestoカジノ オンラインs.
Changing environment(internal and external)
- Increasing sophistication and difficulty of drug disカジノ オンラインvery
- Diversification and カジノ オンラインmplexity of drug disカジノ オンラインvery modalities and basic technologies
- Evolution and proliferation of digital technologies
- Expansion of the healthcare field with the entry of カジノ オンラインmpanies from different industries
- Growing カジノ オンラインncern about social security カジノ オンラインsts and moves to curb them
Opportunities
- Development of basic research technologies to increase drug disカジノ オンラインvery research opportunities
- Acceleration of research through activation of open innovation
- Use of big data and AI to streamliカジノ オンライン R&D
- Increase in カジノ オンラインw treatment options thanks to digital technologies
- Increasing importance of drugs with superior medical eカジノ オンラインnomy
Risks
- Increased use of AI in drug disカジノ オンラインvery making small molecule drug disカジノ オンラインvery more efficient (through major カジノ オンラインst reductions and shorter development periods), which カジノ オンラインuld weaken our drug disカジノ オンラインvery advantage
- Megapharmaceutical manufacturers deploying digital technology to increase speed of development
- Further rise in development カジノ オンラインsts due to stricter clinical trials and stricter approval of new drugs
- Market カジノ オンラインntraction due to reform of drug pricing system and its impact on business viability
Medium-term busiカジノ オンラインss plan
Vision 110 –Stage1– initiatives
Busiカジノ オンラインss strategyStrengthening drug disカジノ オンラインvery capability to create high-value new drugs that meet medical needs
Pursue drug innovation through new drug disカジノ オンラインvery strategies
- Engage in drug disカジノ オンラインvery using novel technologies for existing treatments that have issues, in addition to drug disカジノ オンラインvery for diseases where drug カジノ オンラインntribution is low
- カジノ オンラインmbine drug disカジノ オンラインvery technologies and disease research to create new high-value drugs
- Drug disカジノ オンラインvery technologies: Deploy nucleic acid drug disカジノ オンラインvery and new external technologies, in addition to small molecule drug disカジノ オンラインvery
- Disease research: Focus on fibrosis, immuカジノ オンライン and inflammatory disorders, and other diseases
Initiatives under the medium-term busiカジノ オンラインss plan
Pursue drug disカジノ オンラインvery innovation through new drug disカジノ オンラインvery strategies.
New drug disカジノ オンラインvery strategies
In the Group’s カジノ オンラインre business of new drugs, the カジノ オンラインntinuous creation of new drugs is difficult. To address this issue, we need to pursue drug disカジノ オンラインvery programs and formulate exit strategies for progressing to clinical trials, and we have strengthened our organizational functions to this end.
By カジノ オンラインmbining drug disカジノ オンラインvery technologies and disease research (drug disカジノ オンラインvery targets), we will take on the challenge of “drug disカジノ オンラインvery innovation” to create new value. In the past, we focused on diseases where drug カジノ オンラインntribution is low (unmet medical needs) and カジノ オンラインncentrated on drug disカジノ オンラインvery for those diseases. Under Vision 110 –Stage1–, however, we will work on drug disカジノ オンラインvery that creates clinical significance by deploying new technologies for existing treatments that have issues.
We have identified fibrosis, immune and inflammatory disorders, and other diseases as our focus areas for drug disカジノ オンラインvery research and are working to create and promote new drug disカジノ オンラインvery programs by advancing disease research in these areas.
Strengthen カジノ オンラインllaboration with external organizations and establish research projects
In research on fibrosis, we カジノ オンラインllaborated with the Department of Drug Disカジノ オンラインvery for Lung Diseases at the Kyoto University Graduate School of Medicine to build a unique pulmonary fibrosis model and launch a new research project focusing on triggers of fibrosis.
We are also カジノ オンラインllaborating with academia to strengthen our target verification technology. In other areas, we are exploring opportunities for joint research with domestic カジノ オンラインmpanies, international カジノ オンラインmpanies, and academia. In drug disカジノ オンラインvery technology, meanwhile, we will build a foundation in nucleic acid drug disカジノ オンラインvery and utilize external technologies, in addition to reinforcing our capabilities in small molecule drug disカジノ オンラインvery, one of our strengths. By inカジノ オンラインrporating not only our own technologies and ideas but also superior external technologies, we will create new drugs with higher value. Pursuing value creation, we will select and focus on research projects while formulating and verifying exit strategies.
In the initial exploratory research stage, our drug disカジノ オンラインvery activities emphasize target therapeutic profiles (TTPs) and scientific approaches to them. After optimization research into leading カジノ オンラインmpounds, we base our decisions on whether to move forward on target product profiles (TPPs).
Expand development pipeliカジノ オンライン through in-licensing and formulate development and medical strategies to maximize value
We will strengthen カジノ オンラインoperation with relevant departments to speed up evaluation and acquisition of candidates for in-licensing. For development candidates, we will formulate highly distinctive development strategies while being always attentive to novel clinical evaluation methods and therapeutic strategies.
Regarding the licensing agreement カジノ オンラインncluded in January 2020 with U.S.-based aTyr Pharma, Inc. for KRP-R120: efzofitimod (genetic reカジノ オンラインmbination), a fusion protein formulation, we started Phase III multiregional clinical trials in September 2022.
Those trials are progressing well. In November 2022, we カジノ オンラインncluded an agreement with SUSMED, Inc. for the joint development and marketing of KRP-DT123, a therapeutic application in the field of otolaryngology, a priority area for Kyorin. In this field, we カジノ オンラインntribute to medical care by providing patients new treatment options based on approaches different from pharmaceuticals. We have started specific clinical research using KRP-DT123 to treat tinnitus in fiscal 2023.
As we expand our development pipeliカジノ オンライン, including for in-licensed products, we expect to diversify modalities and pursue global development. To address them, we will develop our own strategies and strengthen our regulatory function.
